Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study
View/ Open
Author
Fay, André P
Callea, Marcella
Telό, Gabriela H
McKay, Rana R
Song, Jiaxi
Carvo, Ingrid
Lampron, Megan E
Kaymakcalan, Marina D
Poli-de-Figueiredo, Carlos E
Hodi, F Stephen
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1186/s40425-015-0047-3Metadata
Show full item recordCitation
Fay, A. P., S. Signoretti, M. Callea, G. H. Telό, R. R. McKay, J. Song, I. Carvo, et al. 2015. “Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.” Journal for Immunotherapy of Cancer 3 (1): 3. doi:10.1186/s40425-015-0047-3. http://dx.doi.org/10.1186/s40425-015-0047-3.Abstract
Background: Adrenocortical carcinoma (ACC) is a rare tumor in which prognostic factors are still not well established. Programmed Death Ligand-1 (PD-L1) expression in ACC and its association with clinico-pathological features and survival outcomes are unknown. Methods: Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from 28 patients with ACC. PD-L1 expression was evaluated by immunohistochemistry (IHC) in both tumor cell membrane and tumor infiltrating mononuclear cells (TIMC). PD-L1 positivity on tumor cells was defined as ≥5% tumor cell membrane staining. TIMC were evaluated by IHC using a CD45 monoclonal antibody. For PD-L1 expression in TIMC, a combined score based on the extent of infiltrates and percentage of positive cells was developed. Any score greater that zero was considered PD-L1 positive. Baseline clinico-pathological characteristics and follow up data were retrospectively collected. Comparisons between PD-L1 expression and clinico-pathological features were evaluated using unpaired t-test and Fisher’s exact test. Kaplan-Meier method and log-rank test were used to assess association between PD-L1 expression and 5-year overall survival (OS). Results: Among 28 patients with surgically treated ACC, 3 (10.7%) were considered PD-L1 positive on tumor cell membrane. On the other hand, PD-L1 expression in TIMC was performed in 27 specimens and PD-L1 positive staining was observed in 19 (70.4%) patients. PD-L1 positivity in either tumor cell membrane or TIMC was not significantly associated with higher stage at diagnosis, higher tumor grade, excessive hormone secretion, or OS. Conclusions: PD-L1 expression can exist in ACC in both tumor cell membrane and TIMC with no relationship to clinico-pathologic parameters or survival. Electronic supplementary material The online version of this article (doi:10.1186/s40425-015-0047-3) contains supplementary material, which is available to authorized users.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357210/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:14351221
Collections
- HMS Scholarly Articles [17917]
Contact administrator regarding this item (to report mistakes or request changes)